T-cell receptor

Overview

The T-cell receptor (TCR) is a membrane-bound antigen receptor expressed by T lymphocytes and is central to adaptive immunity. It recognizes antigenic Peptides presented by major histocompatibility complex molecules, enabling T cells to detect infected, malignant, or otherwise altered cells. In this way, TCR specificity underlies T-cell activation, tolerance, effector function, and the distinction between productive immune responses and anergic or nonresponsive states.

Structurally and functionally, TCRs are most often discussed in the context of their variable regions, especially the complementarity-determining region 3 (CDR3), which contributes strongly to antigen specificity. Because TCR recognition is HLA-restricted and depends on peptide-MHC affinity and avidity, the receptor is a major focus in cancer immunotherapy, infectious disease research, and immune engineering. Recent work has also expanded TCR research into single-cell and spatial multi-omics, computational binding prediction, and engineered cell therapies, including T-cell receptor gene transfer alongside chimeric antigen receptor approaches.

Recent Publications Focus

Below is a summary of the newest research publications targeting T-cell receptor (sorted by publication date).

• 2026-06-15 — Cancer Research (PMID: 41886621)
  This study used a deep learning-driven framework integrating organoid-based functional validation to identify universal neoantigens from recurrent glioma mutations. Within that workflow, TCR recognition features were incorporated into a TCRscore model alongside HLA binding information, highlighting the importance of T-cell receptor specificity in prioritizing candidate neoantigens for immunotherapy. The work reflects a broader trend toward combining computational prediction with functional validation to connect peptide presentation and TCR engagement.

• 2026-06-12 — Science Advances (PMID: 42284409)
  The authors developed ready-to-load MHC-I nanoparticles for high-throughput T cell screening studies. Their rationale centered on the fundamental role of interactions between peptide-MHC molecules and cognate T-cell receptors in determining whether T cells become activated or anergic. This platform is designed to accelerate screening of TCR–antigen interactions by presenting peptide–MHC complexes in a format suitable for systematic testing.

• 2026-06-10 — Genome Medicine (PMID: 42271498)
  This paper introduced circVDJ-seq, a simplified and cost-efficient method for T-cell receptor profiling from 3'-directed workflows, including single-cell and single-nucleus RNA sequencing, ATAC+RNA multi-omics, and spatial transcriptomics. The method addresses the need for scalable TCR clonotype detection in complex datasets, enabling integrated analysis of T-cell states and receptor repertoires across single-cell and spatial platforms.

• 2026-06-08 — Biomedicine & Pharmacotherapy (PMID: 42259140)
  In a preclinical proof-of-concept study of NKG2D-based CAR-T cells for synovial sarcoma, the authors noted that cloned TCR-engineered T cell therapy has already shown promising results in patients with advanced synovial sarcoma. However, they emphasized that the number of eligible patients is limited by HLA restriction, a key biological constraint of TCR-based therapies. This publication situates TCR engineering within the broader landscape of adoptive cell therapy and contrasts it with CAR-based approaches that are not HLA restricted.

• 2026-06-05 — Science Advances (PMID: 42247513)
  This study showed that engaging the endogenous T-cell receptor on CAR T cells with an oncolytic virus can generate a population of effector CAR T cells with potent antitumor activity. The findings suggest that TCR signaling can be leveraged to enhance CAR T-cell functionality and durability, indicating a functional interplay between endogenous TCR pathways and engineered antigen receptors in cell therapy.

• 2026-05-18 — Cell Reports Methods (PMID: 41923632)
  The authors developed a lightweight TcrLM model to predict T-cell receptor and epitope binding specificity. The study is grounded in the principle that immune responses depend on specific interactions between TCRs and peptides presented by antigen-presenting cells. This work contributes to computational TCR–epitope pairing and specificity prediction, which are important for neoantigen discovery and TCR-guided immunotherapy design.

• 2026-05-15 — International Immunopharmacology (PMID: 41846058)
  This systematic review and meta-analysis on NY-ESO-1 in triple-negative breast cancer discussed the structural basis of NY-ESO-1 recognition by T-cell receptors and antibodies, as well as epigenetic regulation of NY-ESO-1 expression through DNA methylation and histone modifications. The publication links TCR biology to tumor antigen recognition in breast cancer and underscores the relevance of antigen expression patterns for immunotherapeutic targeting.

• 2026-05-14 — Biochemical and Biophysical Research Communications (PMID: 41856057)
  The study focused on targeted introduction of T-cell receptor genes at the TRAC locus in cytotoxic T lymphocytes regenerated from human iPSCs by genome editing. The authors referenced prior evidence that introducing tumor antigen-specific TCR genes into iPSC-derived CTLs using retroviral or lentiviral vectors can confer effective antitumor activity. This work reflects ongoing efforts to improve precision, consistency, and genomic control in TCR engineering strategies.

• 2026-04-28 — JCI Insight (PMID: 42048152)
  The authors presented TCXpress, a high-throughput platform that clones fully expressible TCRs from single cells into retroviral or lentiviral vectors without sequencing or gene synthesis. They applied the system to study TCRs from CD8 cells infiltrating mouse MC38 tumors. The study demonstrates a practical route for parallel TCR cloning and testing, supporting anti-neoantigen tumor immunotherapy development.

• 2026-04-28 — ACS Nano (PMID: 41990155)
  This paper introduced a nanovial-based functional screening platform for high-throughput discovery of TCRs from unconventional T cells in human blood, including metabolite-reactive receptors. The work expands TCR discovery beyond conventional peptide-specific repertoires and highlights the potential of functional screening technologies for identifying receptors relevant to cancer therapy.

• 2026-04-20 — Stem Cell Reviews and Reports (PMID: 42008225)
  In a study of placenta- and adipose-derived mesenchymal stromal/stem cells, IFNγ priming selectively expanded the repertoire of exosomal miRNAs and enriched signaling networks including Wnt/β-catenin, TGF-β, NF-κB, and T-cell receptor pathways. Although the primary focus was on secretome modulation for cell-free immunoregenerative therapies in osteochondral and degenerative joint diseases, the inclusion of TCR pathway enrichment suggests immune-relevant signaling changes associated with priming.

• 2026-04-20 — Blood (PMID: 42008381)
  This review on neoantigen-specific T cells for precision immunotherapy in hematologic malignancies emphasized that endogenous T-cell receptors recognize tumor-derived peptides in an HLA-restricted context. The article contrasted this mechanism with CAR T cells, which use synthetic antigen recognition rather than native TCR–peptide–HLA interactions. It reinforces the central role of TCR specificity in neoantigen-directed cancer therapy.

• 2026-04-15 — Clinical Cancer Research (PMID: 41661081)
  This review discussed strategies against checkpoint resistance, including redirection of effector cells through engineered T-cell receptors, chimeric antigen receptors, and CD3/TCR engagers. The publication places TCR engineering among the major modalities used to impose novel tumor specificity on immune effector cells in cancer immunotherapy.

• 2026-04-01 — Nature (PMID: 41851456)
  The paper described in vivo site-specific engineering to reprogram T cells, noting that engineered T cells expressing chimeric antigen receptors or T-cell receptors have transformed cancer treatment and are being explored for autoimmune and infectious diseases. This work situates TCR engineering within broader in vivo cell reprogramming strategies aimed at therapeutic immune modulation.

• 2026-03-27 — Cancer Letters (PMID: 41903669)
  In a study of a circRNA neoantigen vaccine for melanoma, the authors reported that the vaccine enhanced T cell-mediated antitumor responses, increasing T-cell receptor clonotype diversity and expanding TCR clonotypes, especially in CD4+ effector and CD8+ cytotoxic T cells. This finding links vaccine-induced immunity to measurable remodeling of the TCR repertoire and supports the use of clonotype analysis as a readout of antitumor immune activation.

Summary of research themes

Across these publications, the T-cell receptor is consistently treated as the molecular basis of antigen-specific T-cell recognition and a central engineering target in immunotherapy. The studies span several complementary directions: computational prediction of TCR–epitope binding, high-throughput TCR cloning and screening, repertoire profiling with circVDJ-seq and sequencing-based methods, and therapeutic TCR engineering in T cells derived from iPSCs or tumor-infiltrating lymphocytes. Multiple papers also emphasize the biological constraint of HLA restriction, which distinguishes TCR-based therapies from CAR T-cell approaches.

A second major theme is the use of TCR biology as a readout of immune response quality. Vaccine and tumor studies reported changes in TCR clonotype diversity, clonal expansion, and receptor specificity, while functional platforms such as MHC-I nanoparticles and nanovial screening were developed to measure or discover TCR interactions more efficiently. Together, these publications underscore the T-cell receptor as both a mechanistic determinant of adaptive immunity and a practical target for cancer immunotherapy development.

Background PMIDs

• [PMID 42284409]
• [PMID 41923632]
• [PMID 41846058]
• [PMID 41851456]

Method PMIDs

• [PMID 42259140]
• [PMID 42048152]
• [PMID 41886621]

Result PMIDs

• [PMID 42008225]
• [PMID 41903669]

Target PMIDs

• [PMID 42271498]
• [PMID 42247513]
• [PMID 41856057]
• [PMID 41990155]
• [PMID 42008381]
• [PMID 41661081]